From: Real-world costs of autosomal dominant polycystic kidney disease in the Nordics
Proportion (%) of patients using drug class, past 12 months | CKD 1–3 (n = 64) | CKD 4–5 (n = 55) | Dialysis (n = 61) | Transplant (n = 63) | P value |
---|---|---|---|---|---|
Antihypertensives | 84 | 98 | 84 | 87 | 0.0275 |
Phosphate binders | 0 | 21 | 95 | 14 | <0.0001 |
ESAs | 2 | 13 | 80 | 15 | <0.0001 |
Analgesics for kidney paina | 17 | 28 | 25 | 17 | 0.4149 |
Vitamin D analogsa | 14 | 57 | 97 | 43 | <0.0001 |
Immunosupressantsa | 0 | 0 | 7 | 100 | <0.0001 |
Other drugs | 19 | 36 | 90 | 41 | <0.0001 |